"We are fully committed to bringing this breakthrough drug to patients as quickly as possible while backing everything we do ...

MIRA Pharmaceuticals (MIRA) announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved ...

MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...

Fintel reports that on September 30, 2024, Rodman & Renshaw initiated coverage of MIRA Pharmaceuticals (NasdaqCM:MIRA) with a ...

Investment analysts at Rodman & Renshaw began coverage on shares of MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) in a research report issued to clients and investors on Monday ...

MIRA Pharmaceuticals Inc. MIRA shares closed higher Friday following the announcement of promising new preclinical data for its lead development product, Ketamir-2. What To Know: The data ...

Additional information about MIRA Pharmaceuticals is available at: www.mirapharmaceuticals.com. This press release and the statements of MIRA Pharmaceuticals' (or the "Company") management related ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

1 Day SHPH -4.41% DJIA -0.70% Russell 2K -1.19% Health Care/Life Sciences -0.45% ...

Fintel reports that on September 30, 2024, Rodman & Renshaw initiated coverage of MIRA Pharmaceuticals (NasdaqCM:MIRA) with a Buy recommendation. As of September 25, 2024, the average one-year ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...